Monte Rosa Therapeutics (GLUE) officer auto-sells shares to cover RSU tax

Rhea-AI Filing Summary

Monte Rosa Therapeutics Principal Accounting Officer Edmund Dunn reported an automatic sale of 139 shares of common stock. The shares were sold on March 4, 2026 at a price of $17.96 per share to cover tax withholding obligations triggered by the vesting of restricted stock units. According to the disclosure, these sales were automatic and not at Dunn’s discretion. After this tax-related transaction, he beneficially owned 22,554 shares of Monte Rosa Therapeutics common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dunn Edmund

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MA 02118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		139	D	$17.96	22,554	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

	/s/ Phil Nickson, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Monte Rosa Therapeutics (GLUE) disclose in Edmund Dunn’s latest Form 4?

Monte Rosa Therapeutics reported that Principal Accounting Officer Edmund Dunn automatically sold 139 common shares to cover tax withholding from vesting restricted stock units. The transaction occurred at $17.96 per share, and he now directly holds 22,554 common shares after the tax-related sale.

How many Monte Rosa Therapeutics (GLUE) shares did Edmund Dunn sell and at what price?

Edmund Dunn sold 139 shares of Monte Rosa Therapeutics common stock at $17.96 per share. The transaction was linked to covering tax withholding from vesting restricted stock units, and was described as automatic rather than a discretionary open-market sale by the officer.

Why were Edmund Dunn’s Monte Rosa Therapeutics (GLUE) shares sold in this Form 4 filing?

The filing states the 139 Monte Rosa Therapeutics shares were sold to satisfy tax withholding obligations from vesting restricted stock units. These sales were automatic under the company’s procedures and were not executed at Edmund Dunn’s discretion as an independent investment decision.

How many Monte Rosa Therapeutics (GLUE) shares does Edmund Dunn own after this transaction?

Following the automatic tax-withholding sale, Edmund Dunn beneficially owns 22,554 Monte Rosa Therapeutics common shares directly. This figure reflects his holdings after the 139 shares were sold in connection with the vesting of restricted stock units described in the Form 4 disclosure.

Was Edmund Dunn’s Monte Rosa Therapeutics (GLUE) share sale an open-market trade?

Although coded as a sale, the footnote explains the 139 Monte Rosa Therapeutics shares were sold automatically to cover tax withholding on vesting restricted stock units. The transaction was not made at Dunn’s discretion like a typical open-market investment trade.